AAP
CORT icon

Arax Advisory Partners’s Corcept Therapeutics CORT Stock Holding History

Arax Advisory Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.15M Buy
+13,204
New +$797K 0.01% 1135
2026
Q1 		– Sell
-138
Closed -$4.8K – 3905
2025
Q4 		$4.8K Sell
138
-20,657
-99% -$1.62M ﹤0.01% 2881
2025
Q3 		$1.73M Buy
20,795
+20,403
+5,205% +$1.48M 0.02% 504
2025
Q2 		$28.8K Buy
+392
New +$28.4K ﹤0.01% 1499
2025
Q1 		– Sell
-274
Closed -$13.8K – 2743
2024
Q4 		$13.8K Sell
274
-5
-2% -$262 ﹤0.01% 1368
2024
Q3 		$12.9K Hold
279
– – ﹤0.01% 1293
2024
Q2 		$9.06K Buy
+279
New +$7.64K ﹤0.01% 1314

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's CORT Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 13,204 shares worth $1.15M. The stake represents 0.01% of the portfolio and ranks #1135 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CORT as recently as Q4 2025.

Arax Advisory Partners first reported a position in CORT in Q2 2024 and has held it in 7 quarters since. The position peaked at $1.73M in Q3 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Arax Advisory Partners held 13,204 shares of Corcept Therapeutics worth $1.15M as of Q2 2026.
  • Corcept Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Corcept Therapeutics made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1135 holding.
  • Arax Advisory Partners first reported a position in Corcept Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Corcept Therapeutics position peaked at $1.73M in Q3 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.